Business Description
iRadimed Corp
NAICS : 334510
SIC : 3841
ISIN : US46266A1097
Description
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 23.27 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.09 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 30.88 | |||||
| Beneish M-Score | -2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 26.4 | |||||
| 3-Year EBITDA Growth Rate | 226.4 | |||||
| 3-Year EPS without NRI Growth Rate | 137.8 | |||||
| 3-Year FCF Growth Rate | 1 | |||||
| 3-Year Book Growth Rate | 4.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 14.69 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46 | |||||
| 9-Day RSI | 47.73 | |||||
| 14-Day RSI | 48.54 | |||||
| 6-1 Month Momentum % | 4.17 | |||||
| 12-1 Month Momentum % | -4.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.44 | |||||
| Quick Ratio | 7.77 | |||||
| Cash Ratio | 5.92 | |||||
| Days Inventory | 238.92 | |||||
| Days Sales Outstanding | 65.41 | |||||
| Days Payable | 47.1 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.71 | |||||
| Dividend Payout Ratio | 0.1 | |||||
| Forward Dividend Yield % | 1.44 | |||||
| 5-Year Yield-on-Cost % | 0.71 | |||||
| 3-Year Average Share Buyback Ratio | -0.9 | |||||
| Shareholder Yield % | 0.73 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 76.57 | |||||
| Operating Margin % | 30.7 | |||||
| Net Margin % | 26.48 | |||||
| FCF Margin % | 15.87 | |||||
| ROE % | 25.21 | |||||
| ROA % | 21.11 | |||||
| ROIC % | 50.55 | |||||
| ROC (Joel Greenblatt) % | 80.77 | |||||
| ROCE % | 27.45 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 30.67 | |||||
| Forward PE Ratio | 28.71 | |||||
| PE Ratio without NRI | 30.03 | |||||
| Shiller PE Ratio | 60.06 | |||||
| Price-to-Owner-Earnings | 67.79 | |||||
| PEG Ratio | 0.97 | |||||
| PS Ratio | 8.14 | |||||
| PB Ratio | 7.2 | |||||
| Price-to-Tangible-Book | 7.45 | |||||
| Price-to-Free-Cash-Flow | 51.18 | |||||
| Price-to-Operating-Cash-Flow | 43.38 | |||||
| EV-to-EBIT | 24.28 | |||||
| EV-to-EBITDA | 23.38 | |||||
| EV-to-Revenue | 7.45 | |||||
| EV-to-Forward-Revenue | 6.9 | |||||
| EV-to-FCF | 46.83 | |||||
| Price-to-Projected-FCF | 3.3 | |||||
| Price-to-DCF (Earnings Based) | 1.16 | |||||
| Price-to-DCF (FCF Based) | 2.71 | |||||
| Price-to-Median-PS-Value | 0.94 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.2 | |||||
| Price-to-Graham-Number | 3.15 | |||||
| Price-to-Net-Current-Asset-Value | 9.13 | |||||
| Price-to-Net-Cash | 16.5 | |||||
| Earnings Yield (Greenblatt) % | 4.12 | |||||
| FCF Yield % | 1.97 | |||||
| Forward Rate of Return (Yacktman) % | 21.49 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
iRadimed Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 62.546 | ||
| EPS (TTM) (€) | 1.304 | ||
| Beta | 0.32 | ||
| Volatility % | 29.31 | ||
| 14-Day RSI | 48.54 | ||
| 14-Day ATR (€) | 0.832123 | ||
| 20-Day SMA (€) | 38.82 | ||
| 12-1 Month Momentum % | -4.76 | ||
| 52-Week Range (€) | 34.6 - 45.4 | ||
| Shares Outstanding (Mil) | 12.66 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
iRadimed Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
iRadimed Corp Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
iRadimed Corp Frequently Asked Questions
What is iRadimed Corp(STU:46K)'s stock price today?
The current price of STU:46K is €38.60. The 52 week high of STU:46K is €45.40 and 52 week low is €34.60.
When is next earnings date of iRadimed Corp(STU:46K)?
The next earnings date of iRadimed Corp(STU:46K) is 2024-08-02 Est..
Does iRadimed Corp(STU:46K) pay dividends? If so, how much?
The Dividend Yield %  of iRadimed Corp(STU:46K) is 0.71% (As of Today), Highest Dividend Payout Ratio of iRadimed Corp(STU:46K) was 0.1. The lowest was 0.1. And the median was 0.1. The  Forward Dividend Yield % of iRadimed Corp(STU:46K) is 1.44%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers